StreetAlpha.app
Home › Stocks › INTS

Intensity Therapeutics, Inc. (INTS)

$2.78
▼ −9.45%
LAST CLOSE · NOV 17

Intensity Therapeutics is developing INT230-6, a water based cancer treatment injected directly into solid tumors. It last closed at $2.78 on Nov 17, down 9.45% on the day.

AI Auto Pilots
Is INTS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$12.0M
EPS (diluted)
−$3.44
Valuation
Market cap
$9.2M
3.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$8.5M
At Sep 30
Shareholder equity
$7.7M
Shares outstanding
3.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$7.6M−$7.6MFY2022FY2023: −$10.5M−$10.5MFY2023FY2024: −$16.3M−$16.3MFY2024FY2025: −$11.6M−$11.6MFY2025

From INTS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated INTS in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 187.8% upside

Based on 1 analyst who set a price target on INTS in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $2.78.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $2.78
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
StoneXMaintained
Nov 6Buy$8
HC Wainwright & Co.Maintained
Aug 18Buy$7
DateFirmActionRatingPrice target
Nov 6StoneXMaintainedBuy$8
Aug 18HC Wainwright & Co.MaintainedBuy$7
Loading…

Technical Analysis

INTS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 25% below its 50 day average. It is 74% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $2.75, and the nearest resistance the Pivot R1 at $2.85.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.5%/day
Key levels
$15.0052 week high+439.6%
$4.83200 day average+73.7%
$3.94100 day average+41.7%
$3.4850 day average+25.2%
$3.39Swing high (Nov 11)+21.9%
$3.2020 day average+15.1%
$2.85Pivot R1+2.5%
$2.78Last close
$2.75Pivot−1.1%
$2.68Pivot S1−3.6%
$2.6552 week low−4.7%
Indicators
RSI (14)36.51Weak, oversold below 30Neutral
MACD-0.14Below its signal lineBearish
Stochastic28.5Middle of its rangeNeutral
ADX (14)14.8No clear trend
Williams %R-85.9Oversold below −80, overbought above −20Oversold
CCI (20)-217.0Oversold below −100, overbought above 100Oversold
Rate of change−14.5%Change over 10 sessionsBearish
ATR (14)$0.29Typical daily range, 10.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for INTS

What happened before

See how INTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow INTS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INTS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in INTS in the last 90 days.

Loading…

See today’s whale options flow across the market →

INTS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼5 buying vs 8 selling
  • ▲Held by funds +6.1 pts
  • ▼Funds holding -1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1516−6.3%
In funds' top 10110.0%
Held by funds26.5%20.4%+6.1 pts
New / increased2 / 33 / 4−28.6%
Reduced / sold out5 / 32 / 1+166.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INTS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INTS is in one of them and how their past INTS trades turned out.

INTS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INTS in an article yet. Here's the latest on the wider market.

About Intensity Therapeutics

Intensity Therapeutics is a clinical stage biotechnology company based in Shelton, Connecticut. It is developing INT230-6, a water based treatment that is injected directly into solid tumors. The candidate combines two established chemotherapy drugs, cisplatin and vinblastine sulfate, with a molecule that helps them spread through the tumor. The company is aiming the treatment at patients with solid cancers, such as breast cancer and sarcoma, and it does not yet have an approved product for sale.

Headquarters
Shelton, CT